Table 1 Demographic, clinical and ultrasonographic data of the study population at baseline
| Â | N= 161 |
|---|---|
Age, years, median (IQR) | 64 (50 to 73) |
F/M (%) | 112/49 (69.6) |
Disease duration, months, median (IQR) | 3 (2 to 6) |
DAS44, mean (± SD) | 3.61 (0.96) |
SDAI, mean (± SD) | 31.53 (13.82) |
SJC, median (IQR) | 12 (8 to 18) |
TJC, median (IQR) | 12 (6 to 18) |
RAI, median (IQR) | 8 (5 to 11) |
GH, 0 to 100 mm, median (IQR) | 56 (50 to 73) |
EGA, 0 to 10 cm, median (IQR) | 4.6 (3.5 to 6) |
PGA, 0 to 10 cm, median (IQR) | 6 (4.8 to 8) |
HAQ, median (IQR) | 1.25 (0.75 to 1.88) |
ESR, mm/h, median (IQR) | 28.5 (17 to 46.5) |
CRP, mg/dl, median (IQR) | 1.19 (0.41 to 3.12) |
IgM RF-positive, n. (%) | 92 (57.1) |
IgM RF titre, UI/ml, median (IQR) | 69 (30.5 to 174) |
IgG ACPA-positive, n. (%) | 79 (49.1) |
IgG ACPA titre, UI/ml, median (IQR) | 100 (42.7 to 292.5) |
US-GS score, median (IQR) | 10 (5 to 12) |
US-PD positive, n. (%) | 122 (75.8) |
US-PD score, median (IQR) | 3.5 (1 to 8) |